KR920006313A - 설폰아미드 피브리노겐 수용체 길항제 - Google Patents

설폰아미드 피브리노겐 수용체 길항제 Download PDF

Info

Publication number
KR920006313A
KR920006313A KR1019910016836A KR910016836A KR920006313A KR 920006313 A KR920006313 A KR 920006313A KR 1019910016836 A KR1019910016836 A KR 1019910016836A KR 910016836 A KR910016836 A KR 910016836A KR 920006313 A KR920006313 A KR 920006313A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
compound according
aralkyl
aryl
Prior art date
Application number
KR1019910016836A
Other languages
English (en)
Other versions
KR100216939B1 (ko
Inventor
에스.에그버트슨 멜리사
디.하트만 조오지
할크젠코 웨이실
엘. 라스웰 윌리암
이. 듀간 마크
Original Assignee
제임스 에프. 너턴
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 너턴, 머크 앤드 캄파니 인코포레이티드 filed Critical 제임스 에프. 너턴
Publication of KR920006313A publication Critical patent/KR920006313A/ko
Application granted granted Critical
Publication of KR100216939B1 publication Critical patent/KR100216939B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)

Abstract

내용 없음

Description

설폰아미드 피브리노겐 수용체 길항제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (50)

  1. 하기 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용 되는 염.
    상기식에서, R1은 1,2,3 또는 4개의 헤테로원자를 함유하는 4내지 8원 헤테로사이클릭 환[여기서, 헤테로원자는 N,O 또는 S이고, 헤테로환은 H,R6또는 R7, NR6R7,
    의해 어떠한 원자에서도 임의로 치환되며, R6및 R7은 독립적으로 수소, 비치환되거나 치환된 C0-10알킬 또는 사이클로알킬(여기에서, 치환체는 C1-10알콕시, C1-10알콜시알킬, C1-10알콕시 알킬옥시, C1-10알콕시카보닐, C1-10알킬카보닐, C1-10아프알킬카보닐, C1-10알킬티오카보닐, 또는 C1-10아르알킬티오카보닐, 티오카보닐, C1-10알콕시티오카보닐, 또는 아릴이거나, N,O 및 S로 이루어진 그룹중에서 선택된 1내지 4개의 헤테로 원자를 함유하는 5내지 6원 포화 헤테로사이클릭 환이거나, C1-4알카노일아미노, C1-5알콕시카보닐-C0-5알킬아미노, C1-10알킬설포닐아미노, C4-10아르알킬설포닐아미노, C4-10아르알킬, C1-10알카릴, C1-10알킬티오, C4-10아르알킬티오, C1-10알킬설포피닐, C4-10아르알킬설피닐, C1-10알킬설포닐,C4-10아르알킬설포닐, 아미노설포닐, C1-10알킬아미노설포닐, C4-10아르알킬설포닐아미노, 옥소 또는 티오이거나, 수소, C1-10알킬
    및 C4-10아프알킬로 이루어진 그룹중에서 선택된 치환체에 의해 일치환되거나 이치환되거나 비치환된 1-에테닐, 2-에테닐, 또는 3-프로페닐 이거나, 카복시, 하이드록시, 아미노, C1-6알킬아미노, C1-6디알킬아미노, F, Cl, Br 또는 I, 니트로 또는 시아노이다)이고, N은 상기 정의된 R6또는 R7에 의해 추가로 치환되어 4급 암모늄 이온을 형성할 수 있다]이고, R2및 R3은 독립적으로 수소, 아릴, 비치환되거나 치환된 C0-10알킬 또는 사이클로알킬[여기서, 치환체는 C1-10알콕시알킬이거나, 아릴이거나, N,O 및 S로 이루어진 그룹중에서 선택된 1내지 4개의 헤테로원자를 함유하는 4내지 8원 포화된 헤테로사이클릭환 시스템이거나, C4-10아르알킬,C1-10알카릴, ,C1-10알킬티오, C4-10아르알킬티오, C1-10알킬설피닐,C4-10아르알킬설피닐, C1-10알킬설포닐, C4-10아르알킬설포닐, 카복시, C1-10알킬카보닐, C1-10알킬티오카보닐, C4-10아르알킬카보닐, C4-10아르알킬티오카보닐, C1-5알콕시카보닐, C4-10아르알콕시키보닐, C1-5알콕시. C1-5알콕시카보닐, C1-6알킬, C4-10아르알콕시카보닐-C1-4알킬, C4-10아르알콕시, C1-5알킬아미노, C1-12디알킬아미노, C1-5알카노일아미노, C4-10아르알카노일아미노, 또는 C4-10아르알킬아미노이다]이며, R4는 알릴, C1-10알킬 또는 사이클로알킬, C4-10아르알킬, C1-10알콕시알킬, C1-10알카릴, C1-10알킬티오알킬, C1-10알콕시티오알킬, C1-10알킬아미노, C4-10아르알킬아미노, C1-10알카노일아미노, C4-10아르알카노일아미노, C1-10알카노일, 또는 C4-10아르알카노일이거나, 치환된 또는 비치환된 C1-10카복시알킬(여기서, 치환체는 아릴 또는 C1-10아르알킬이며, 또한 R4에 대한 치환체는 R6에 대해 정의된 그룹상에서 선택된 치환체에 의해 치환될 수 있다)이고, R5는 N,O 또는 S인 헤테로원자 1,2,3 또는 4개를 함유하는 4내지 8원 포화 또는 불포화 헤테로사이클릭환,(여기서, R8은 하드록시, C1-10알킬옥시, C1-10알카릴옥시, C4-10아르알킬옥시, C4-10아르알킬카보닐옥시, C1-10알콕시알킬옥시, C1-10알콕시알킬카보닐옥시, C1-10알콕시카보닐알킬, C1-10알킬카보닐옥시알킬옥시, 아미드 결합에 의해 연결된 L- 또는 D-아미노산, 또는 아미노산의 카복실산 잔기가 C1-5알킬 또는 C4-10아르알킬에 의해 에스테르화되고 아미드 결합에 의해 연결된 L- 또는 D-아미노산이다.),(여기서, R9및 R10은 수소, C1-10알킬 및 C4-10아르알킬로 이루어진 그룹중에서 선택된다)이며, X및 Y는 독립적으로, NR6, O,S,SO,SO2,R6R7, -C=C- 또는 -C≡C- 이거나, N,O 및 S중에서 선택된 0,1,2,3 또는 4개의 헤테로원자를 함유하는 4-내지 8-원 환(여기서, 환은 R6, 아릴,에 의해 어떠한 원자에서도 독립적으로 치환될 수 있다)이고, Z는, 존재하는 경우, X 및 Y에 대해 정의된 바중에서 독립적으로 선택된 임의 치환체이며, m은 0내지 10의 정수이고, n은 0내지 10의 정수이며, p,는 0내지 3의 정수이다.
  2. 일반식(Ⅱ)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, R1은 4내지 8원 헤테로사이클릭환[여기서, 헤테로 원자는 N, O 또는 S이고, 헤테로사이클릭 환은 C1-10알킬, 또는 NR6R7(여기서, R6및 R7은 독립적으로 수소이거나, C1-10알콕시카보닐, 아릴, C0-5디알킬아미노-C1-10알킬 또는 C4-10아르알킬에 의해 치환되거나, 비치환된 C1-10알킬이다)에 의해 임의로 치환되며, N은 R6및 R7에 대해 정의된 바와 같은 치환체에 의해 추가로 치환되어 4급 암모늄 이온을 형성할 수 있다)로 임의로 치환된다]이고, Z는, 존재하는 경우, O, SO2, -NR6CO-, -CONR6,-SO2NR6- 도는 -NR6SO2- 이거나, N O 또는 S중에서 선택된 0, 1 또는 2개의 헤테로원자를 함유하는 5 또는 6원환(여기에서, 환은 R6과 함께 특정 원자에서 독립적으로 치환된다)이고, Z는 존재하는 경우, O, SO2, -NR6CO-, -CONR6-,직쇄 또는 측쇄 알킬인 임의의 치환체이며, n은 0내지 2의 정수이며, p는 0내지 2의 정수이다.
  3. 일반식(Ⅱ-a)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, R1은 1 또는 2개의 헤테로원자를 갖는 4내지 6원 헤테로사이클릭환[여기서, 헤테로원자는, N,O 또는 S이고, 헤테로사이클릭 환은 C1-10알킬, 또는 NR6R7(여기서, R6및 R7은 독립적으로 수소이거나, C4-10아르알킬에 의해 치환되거나 비치환된 C1-10알킬이다)에 의해 임의로 치환되며, N은 R6및 R7에 대해 정의된 바와 같은 치환체에 의해 추가로 치환되어 4급암모늄 이온을 형성할 수 있다]이고, R2및 R3은 수소이고, R4는 아릴, C4-10아르알킬이고, R11은 수소 또는 C1-10알킬이며, X 및 Y는 독립적으로 O,-CH=CH-, -CH2-, 또는 C1-10아르알킬사이클로알킬이고, Z는, 존재하는 경우 O, SO2, -NHCO- 또는 C1-10직쇄 또는 측쇄 알킬인 임의의 치환체이며, m은 0내지 6의정수이고, n은 0내지 1의 정수이며, p는 0내지 1의 정수이다.
  4. 일반식(Ⅱ-b)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, R1은 1 또는 2개의 헤테로원자를 갖는 4내지 6원 헤테로사이클릭환[여기서, 헤테로원자는, N 또는 O이고, 헤테로사이클릭 환은 C1-10알킬에 의해 임의로 치환된다), 또는 NR6R7(여기서, R6및 R7은 독립적으로 수소 또는 C1-10알킬이다)이고, R4는 아릴, C1-10알킬 또는 C4-10아르알킬이며, X 및 Y는 독립적으로, C1-10알킬
    또는 사이클로알킬,Z는, 존재하는 경우 O, -NHCO- 또는-CONH-, C1-15직쇄 또는 측쇄 알킬이며, m은 0 또는 6의정수이고, n은 0 또는 2의 정수이며, p는 0 또는 1이다.
  5. 일반식(Ⅲ)의 화합물.
    상기식에서, R1은 1 또는 2개의 헤테로원자를 갖는 4내지 6원 헤테로사이클릭환[여기서, 헤테로원자는 N 이다.), 또는 NR6R7(여기서, R6및 R7은 독립적으로 H 또는 C1-10알킬이며, Z는, 존재하는 경우 O,이고, m은 2내지6의 정수이다.
  6. 5항에 있어서, 하기 구조식의 화합물;
  7. 제5항에 있어서, 하기 구조식의 화합물.
  8. 제5항에 있어서, 하기 구조식의 화합물.
  9. 제5항에 있어서, 하기 구조식의 화합물.
  10. 제1항에 있어서, 하기 구조식의 화합물.
  11. 제1항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  12. 제6항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  13. 제7항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  14. 제8항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  15. 제9항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  16. 제10항에 따른 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  17. 포유동물에 제1항에 따른 화합물의 약리학적 유효량을 투여하는 단계를 포함함을 특징으로 하여, 포유동물에서 피브리노겐의 혈소판 수용체 부위에서의 작용으로부터 피브리노겐을 차단시키는 방법.
  18. 제17항에 있어서, 화합물이 제6항에 따른 화합물인 방법.
  19. 제17항에 있어서, 화합물이 제7항에 따른 화합물인 방법.
  20. 제17항에 있어서, 화합물이 제8항에 따른 화합물인 방법.
  21. 제17항에 있어서, 화합물이 제9항에 따른 화합물인 방법.
  22. 제17항에 있어서, 화합물이 제10항에 따른 화합물인 방법.
  23. 혈전 형성 억제가 필요한 포유동물에게 제1항에 따른 화합물의 약리학적 유효량을 투여하는 단계를 포함함을 특징으로 하여, 혈전 형성물 억제하는 방법.
  24. 제23항에 있어서, 화합물이 제6항에 따른 화합물인 방법.
  25. 제23항에 있어서, 화합물이 제7항에 따른 화합물인 방법.
  26. 제23항에 있어서, 화합물이 제8항에 따른 화합물인 방법.
  27. 제23항에 있어서, 화합물이 제9항에 따른 화합물인 방법.
  28. 제23항에 있어서, 화합물이 제10항에 따른 화합물인 방법.
  29. 혈전 형성 치료가 필요한 포유동물에게 제1항에 따른 화합물의 약리학적 유효량을 투여하는 단계를 포함함을 특징으로 하여, 혈전 형성의 치료가 필요한 포유동물의 혈정 형성을 치료하는 방법.
  30. 제29항에 있어서, 화합물이 제6항에 따른 화합물인 방법.
  31. 제29항에 있어서, 화합물이 제7항에 따른 화합물인 방법.
  32. 제29항에 있어서, 화합물이 제8항에 따른 화합물인 방법.
  33. 제29항에 있어서, 화합물이 제9항에 따른 화합물인 방법.
  34. 제29항에 있어서, 화합물이 제10항에 따른 화합물인 방법.
  35. 제23항에 있어서, 화합물이 항응고제와 공동 투여되는 방법.
  36. 제29항에 있어서, 화합물이 항응고제와 공동 투여되는 방법.
  37. 제23항에 있어서, 화합물이 섬유소 용해제와 공동투여되는 방법.
  38. 제29항에 있어서, 화합물이 섬유소 용해제와 공동투여되는 방법.
  39. 제35항에 있어서, 화합물이 제9항에 따른 화합물인 방법.
  40. 제35항에 있어서, 화합물이 제10항에 따른 화합물인 방법.
  41. 제23항에 있어서, 화합물이 항응고제와 공동 투여되는 방법.
  42. 제29항에 있어서, 화합물이 항응고제와 공동 투여되는 방법.
  43. 제35항에 있어서, 화합물이 혈소판 응고제와 공동투여 되는 방법.
  44. 제23항에 있어서, 화합물이 섬유소 용해제와 공동투여되는 방법.
  45. 제29항에 있어서, 화합물이 섬유소 용해제와 공동투여되는 방법.
  46. 제35항에 있어서, 화합물이 섬유소 용해제와 공동투여되는 방법.
  47. 제23항에 있어서, 화합물이 혈소판 항응집제와 공동투여 되는 방법.
  48. 제29항에 있어서, 화합물이 혈소판 항응집제와 공동투여 되는 방법.
  49. 제35항에 있어서, 화합물이 혈소판 항응집제와 공동투여 되는 방법.
  50. 제11항에 있어서, 혈소판 항응집제, 혈전 용해제 및 항응고제로 이루어진 그룹중에서 선택된 화합물을 추가로 함유하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910016836A 1990-09-27 1991-09-26 설폰아미드 피브리노겐 수용체 길항제 KR100216939B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58913090A 1990-09-27 1990-09-27
US7/589,130 1990-09-27
US07/589,130 1990-09-27
US75064791A 1991-08-30 1991-08-30
US07/750647 1991-08-30
US7/750,647 1991-08-30

Publications (2)

Publication Number Publication Date
KR920006313A true KR920006313A (ko) 1992-04-27
KR100216939B1 KR100216939B1 (ko) 1999-09-01

Family

ID=27080454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910016836A KR100216939B1 (ko) 1990-09-27 1991-09-26 설폰아미드 피브리노겐 수용체 길항제

Country Status (33)

Country Link
US (5) US5292756A (ko)
EP (2) EP0478363B1 (ko)
JP (2) JPH0794425B2 (ko)
KR (1) KR100216939B1 (ko)
CN (1) CN1038748C (ko)
AT (1) ATE150454T1 (ko)
AU (1) AU655436B2 (ko)
BG (1) BG61810B1 (ko)
CA (1) CA2052073C (ko)
CY (1) CY2048B1 (ko)
DE (2) DE19875054I2 (ko)
DK (1) DK0478363T3 (ko)
ES (2) ES2133892T3 (ko)
FI (2) FI108295B (ko)
GR (2) GR3023226T3 (ko)
HK (1) HK1000509A1 (ko)
HR (1) HRP930779B1 (ko)
IE (1) IE913383A1 (ko)
IL (1) IL99540A (ko)
LU (1) LU90505I2 (ko)
LV (1) LV12089B (ko)
NL (1) NL990040I2 (ko)
NO (2) NO177702C (ko)
NZ (1) NZ239846A (ko)
PL (1) PL172687B1 (ko)
PT (1) PT99098B (ko)
RO (1) RO116621B1 (ko)
RU (1) RU2116296C1 (ko)
SI (1) SI9210306B (ko)
SK (1) SK281233B6 (ko)
UA (1) UA44222C2 (ko)
WO (1) WO1993019046A1 (ko)
YU (1) YU48912B (ko)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ATE160147T1 (de) * 1991-09-24 1997-11-15 Janssen Pharmaceutica Nv Verfahren zur herstellung von enantiomer reinem imidazo (4,5,1-jk) (1,4)-benzodiazepin-2(1h)- thionen
US5264457A (en) * 1992-02-14 1993-11-23 G. D. Searle & Co. Phenyl amidines sulfonamides useful as platelet aggregation inhibitors
TW224462B (ko) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5312923A (en) * 1992-02-28 1994-05-17 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5206373A (en) * 1992-02-28 1993-04-27 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
US5504106A (en) * 1992-06-25 1996-04-02 G. D. Searle & Co. Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
JPH08502484A (ja) * 1992-10-14 1996-03-19 メルク エンド カンパニー インコーポレーテッド フィブリノゲンリセプタ拮抗剤
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US5786373A (en) * 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9406143D0 (en) * 1993-03-29 1994-05-18 Zeneca Ltd Heterocyclic derivatives
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
CA2155307A1 (en) * 1993-03-29 1994-10-13 Michael Garth Wayne Heterocyclic compounds as platelet aggregation inhibitors
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5612355A (en) * 1993-06-23 1997-03-18 G. D. Searle & Co. Phenyl amidine lactones useful as platelet aggregation inhibitors
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5607948A (en) * 1993-06-30 1997-03-04 Sumitomo Pharmaceuticals Co., Ltd. Dipiperidine derivatives
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0725059B1 (en) * 1993-10-19 2001-01-17 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0799189A4 (en) * 1994-12-13 1999-03-17 Smithkline Beecham Corp BICYCLIC FIBRINOGENIC ANTAGONISTS
WO1996019223A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118007A0 (en) * 1995-05-24 1996-08-04 Du Pont Merck Pharma Isoxazoline compounds pharmaceutical compositions containing them and their use
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
AU702487B2 (en) * 1995-08-30 1999-02-25 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
US5789421A (en) * 1995-10-26 1998-08-04 Merck & Co., Inc. Fibrinogen receptor antagonist
US5972967A (en) * 1996-10-23 1999-10-26 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US5733919A (en) * 1995-10-27 1998-03-31 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
TW385248B (en) * 1995-10-27 2000-03-21 Merck & Co Inc Pharmaceutical compositions for intravenous administration for inhibiting platelet aggregation
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
AU712082B2 (en) * 1996-02-28 1999-10-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
AU2340997A (en) * 1996-03-27 1997-10-17 Merck & Co., Inc. A method for inhibiting clot formation
AU2420897A (en) 1996-03-29 1997-10-22 G.D. Searle & Co. Meta-substituted phenylene sulphonamide derivatives
ATE219764T1 (de) * 1996-03-29 2002-07-15 Searle & Co Zimtsäurederivate und deren verwendung als integrin-antagonisten
ES2162676T3 (es) * 1996-03-29 2002-01-01 Searle & Co Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
DK0889875T3 (da) * 1996-03-29 2001-09-03 Searle & Co Cycloproylalkansyrederivater
PT891325E (pt) * 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
EP0925063A4 (en) 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
EP0922039A1 (en) * 1996-08-15 1999-06-16 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US5978698A (en) * 1996-10-08 1999-11-02 Merck & Co., Inc. Angioplasty procedure using nonionic contrast media
DK0946185T4 (da) * 1996-11-27 2010-08-30 Aventis Pharma Inc Farmaceutisk præparat, som omfatter en forbindelse med anti-Xa-aktivitet og en blodpladeaggregations antagonistforbindelse
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
AU1523199A (en) * 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
ES2317688T3 (es) 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO1999038827A1 (en) * 1998-02-02 1999-08-05 Merck & Co., Inc. PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6117842A (en) * 1998-03-09 2000-09-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000026161A1 (fr) * 1998-11-04 2000-05-11 Rhodia Chimie Procede et reactif de sulfonylation utiles pour la synthese de sulfanilide perhalogene
ES2339738T3 (es) 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.
CA2359112A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
CN1231212C (zh) 1999-01-22 2005-12-14 依兰制药公司 抑制vla－4介导的白细胞粘着的多环化合物
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100377558B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
KR100377557B1 (ko) * 1999-02-12 2003-03-26 주식회사 엘지생명과학 아실 구아니딘 작용기를 갖는 선택적 트롬빈 억제제
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US6348504B1 (en) 1999-03-30 2002-02-19 Richard E. Olson Oxime ethers as IIb/IIa antagonists
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
TR200400105T4 (tr) 1999-12-10 2004-02-23 Prizer Products Inc. Pirrolo [2,3-d] pirimidin bileşikleri
ES2237482T3 (es) * 1999-12-27 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados de aminoalquilamidas sustituidas como antagonistas de la hormona estimuladora de los foliculos.
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
KR20030027106A (ko) * 2000-08-30 2003-04-03 파마시아 코포레이션 젬-치환 알파 ｖ 베타 3 인테그린 길항제
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
KR100948278B1 (ko) * 2002-02-07 2010-03-18 히토시 엔도 방향족 아미노산 유도체 및 의약 조성물
US6770660B2 (en) * 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CN100422147C (zh) * 2002-11-01 2008-10-01 北京天衡药物研究院 一种制备0-取代磺酰酪氨酸类化合物的方法
OA12960A (en) * 2002-11-15 2006-10-13 Cadila Healthcare Ltd Substituted aralkyl derivatives.
BR0316470A (pt) 2002-11-21 2005-10-11 Pfizer Prod Inc Derivados de 3-amino-piperadina e métodos de preparação
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
EP1685135B1 (en) * 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
DE10356346A1 (de) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
NZ567270A (en) * 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2851103A1 (en) 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
KR20080100271A (ko) * 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR20110108330A (ko) 2008-11-21 2011-10-05 이로코 카디오, 엘엘씨 혈소판감소증 및 혈소판감소증-관련 사망을 감소시키기 위한 티로피반의 약학적으로 허용가능한 염
EP2408440B1 (en) 2009-03-18 2016-05-11 Medicure International Inc. Transdermal pharmaceutical preparation and administration of tirofiban
EP2424841A1 (en) * 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Pyridinone antagonists of alpha-4 integrins
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
DK2744802T3 (en) 2011-08-17 2017-04-03 Piramal Imaging Sa CONNECTIONS FOR BINDING TO THE TROMBOCYTE SPECIFIC GLYCOPROTEIN IIB / IIIA AND ITS APPLICATION FOR IMAGE DIAGNOSIS OF TROMBER
CN103848775A (zh) * 2012-11-29 2014-06-11 上海信谊药厂有限公司 制备盐酸替罗非班的方法
US20160008490A1 (en) 2013-02-12 2016-01-14 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN115181058B (zh) * 2021-04-01 2024-06-11 武汉武药科技有限公司 组合物及其质量控制方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4098889A (en) * 1977-09-01 1978-07-04 The Dow Chemical Company Antithrombotic 2-(aminoalkylthio)-N,N'-p-phenylenebissulfonamides
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IL60129A0 (en) * 1979-05-23 1980-07-31 Wuelfing J Kg Phenylsulphonamide derivatives,their preparation and pharmaceutical compositions containing them
FR2482528A1 (fr) * 1980-05-14 1981-11-20 Heuliez Henri Holding Vehicule automobile a deux modes de traction, notamment autobus
US5174994A (en) * 1985-11-11 1992-12-29 Leuven Research & Development Vzw Pharmaceutical composition having thrombolytic activity
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
PH25458A (en) * 1987-08-24 1991-07-01 Eisai Co Ltd Piperidine derivatives, therapeutic, preventive agents
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0743302A3 (en) 1997-03-05
NO913784D0 (no) 1991-09-26
CA2052073A1 (en) 1992-03-28
BG61810B1 (bg) 1998-06-30
DE19875054I2 (de) 2007-05-24
JPH04288051A (ja) 1992-10-13
EP0743302A2 (en) 1996-11-20
GR3031473T3 (en) 2000-01-31
NO913784L (no) 1992-03-30
YU30692A (sh) 1995-10-24
FI20011201A (fi) 2001-06-06
PL172687B1 (pl) 1997-11-28
SK102394A3 (en) 1995-04-12
US5292756A (en) 1994-03-08
IL99540A (en) 1995-07-31
PT99098A (pt) 1992-08-31
JP2812431B2 (ja) 1998-10-22
ATE150454T1 (de) 1997-04-15
UA44222C2 (uk) 2002-02-15
KR100216939B1 (ko) 1999-09-01
HRP930779A2 (en) 1997-02-28
ES2133892T3 (es) 1999-09-16
EP0478363B1 (en) 1997-03-19
NO2000001I2 (no) 2005-09-26
YU48912B (sh) 2002-11-15
GR3023226T3 (en) 1997-07-30
BG99020A (bg) 1995-07-28
DK0478363T3 (da) 1997-05-12
CN1069971A (zh) 1993-03-17
PT99098B (pt) 1999-02-26
LV12089A (lv) 1998-07-20
NO177702C (no) 1995-11-08
WO1993019046A1 (en) 1993-09-30
US5880136A (en) 1999-03-09
FI914534A0 (fi) 1991-09-26
NO177702B (no) 1995-07-31
RU2116296C1 (ru) 1998-07-27
AU8478291A (en) 1992-04-02
SI9210306B (sl) 1998-06-30
SI9210306A (en) 1995-08-31
ES2100214T3 (es) 1997-06-16
NL990040I2 (nl) 2000-03-01
US6040317A (en) 2000-03-21
LV12089B (en) 1998-11-20
NZ239846A (en) 1994-11-25
HRP930779B1 (en) 2000-08-31
AU655436B2 (en) 1994-12-22
EP0478363A3 (en) 1992-08-19
RU94041739A (ru) 1996-08-10
DE69125235T2 (de) 1997-08-07
IL99540A0 (en) 1992-08-18
LU90505I2 (fr) 2000-03-20
EP0743302B1 (en) 1999-08-04
EP0478363A2 (en) 1992-04-01
IE913383A1 (en) 1992-04-08
CY2048B1 (en) 1998-04-30
CA2052073C (en) 1998-04-14
JPH09132558A (ja) 1997-05-20
JPH0794425B2 (ja) 1995-10-11
SK281233B6 (sk) 2001-01-18
US5814643A (en) 1998-09-29
US5658929A (en) 1997-08-19
HK1000509A1 (en) 1998-04-03
FI108295B (fi) 2001-12-31
CN1038748C (zh) 1998-06-17
NL990040I1 (nl) 2000-02-01
RO116621B1 (ro) 2001-04-30
FI914534A (fi) 1992-03-28
DE69125235D1 (de) 1997-04-24

Similar Documents

Publication Publication Date Title
KR920006313A (ko) 설폰아미드 피브리노겐 수용체 길항제
ES2210339T3 (es) Medicamentos para el tratamiento de cardiopatias inflamatorias.
KR940701259A (ko) 바이사이클릭 피브리노겐 길항제
RU96121561A (ru) Применение антагонистов серотонина (5ht3) для лечения фибромиалгии
KR920006298A (ko) 피브리노겐 수용체 길항제
RU97107338A (ru) Новые соединения
ES2029769A6 (es) Procedimiento para preparar medicamentos a base de acidos carboxilicos que contienen azufre como sustancia activa.
KR960705575A (ko) 비스포스포네이트와 성장 호르몬 분비촉진제와의 배합물(Combination of bishosphonates and growth hormone secretagogues)
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
KR890701587A (ko) 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
KR870700067A (ko) 피리도(2,3-d)-피리미딘 유도체
RU2006106701A (ru) Антагонистические аналоги gh-rh (2003)
CA2100830A1 (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
NO163452C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive karbapenemderivater.
KR920000759A (ko) 3,7-디아자비시클로[3,3,1]노난 화합물을 함유하는 신규의 의약품
KR910018014A (ko) 합성 지질을 포함하는 비경구적으로 투여가능한 리포좀 제형
KR970061255A (ko) 폴리포스포네이트 또는 프로게스틴과 함께 에스트로겐 작용 물질을 사용하여 골다공증을 치료하기 위한 약학 조성물
KR950704322A (ko) 스피로푸라논 유도체 및 그의 신경변성 질환 치료 용도(Spirofuranone Derivatives and Their Use in the Treatment of Neurodegenerative Disorders)
KR890002149A (ko) 피롤로 이소퀴놀린 유도체 및 그의 제조방법
RU2001132327A (ru) Применение макролидных соединений для лечения сухости глаза
GB1164526A (en) Bis(Carbonylamino-Triiodobenzoic Acids), Their Derivatives and Preparation Thereof
SE8303718L (sv) E-homo-enurnanderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110630

Year of fee payment: 13

EXPY Expiration of term